{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:17:01Z","timestamp":1791335821123,"version":"4.3.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004572","name":"National Health and Family Planning Commission","doi-asserted-by":"crossref","award":["201402031"],"award-info":[{"award-number":["201402031"]}],"id":[{"id":"10.13039\/501100004572","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lung Cancer Translational Medicine","award":["2012A061400006"],"award-info":[{"award-number":["2012A061400006"]}]},{"name":"Guangzhou Science and Technology Bureau","award":["2011Y2-00014"],"award-info":[{"award-number":["2011Y2-00014"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2014A030310485"],"award-info":[{"award-number":["2014A030310485"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jtho.2016.06.029","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T14:06:14Z","timestamp":1471269974000},"page":"1962-1969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":281,"title":["Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations"],"prefix":"10.1016","volume":"11","author":[{"given":"Yang-Si","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Bang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.06.029_bib1","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2005.01.131","article-title":"Neoplastic meningitis","volume":"23","author":"Chamberlain","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","article-title":"Neoplastic meningitis","volume":"5","author":"Gleissner","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jtho.2016.06.029_bib3","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non\u2013small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jocn.2015.11.012","article-title":"Management of leptomeningeal metastases: prognostic factors and associated outcomes","volume":"27","author":"Brower","year":"2016","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.jtho.2016.06.029_bib5","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.4103\/2152-7806.111304","article-title":"Carcinomatous meningitis: leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.jtho.2016.06.029_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","article-title":"Leptomeningeal metastasis: clinical experience of 519 cases","volume":"56","author":"Hyun","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non\u2013small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib8","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/ijc.21940","article-title":"Frequent EGFR mutations in brain metastases of lung adenocarcinoma","volume":"119","author":"Matsumoto","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","article-title":"High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib","volume":"103","author":"Omuro","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged survival of patients with non\u2013small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/1759-7714.12188","article-title":"Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer","volume":"6","author":"Xu","year":"2014","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.lungcan.2015.06.001","article-title":"Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations","volume":"89","author":"Gong","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-014-0326-9","article-title":"Erlotinib in combination with pemetrexed\/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure","volume":"10","author":"Yang","year":"2015","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"\u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib19","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00280-011-1555-6","article-title":"Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy","volume":"67","author":"Masuda","year":"2011","journal-title":"Cancer Chemoth Pharm"},{"key":"10.1016\/j.jtho.2016.06.029_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)\u2013pretreated non\u2013small-cell lung cancer patients with brain metastases or leptomeningeal disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","article-title":"High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs","volume":"75","author":"Kawamura","year":"2015","journal-title":"Cancer Chemoth Pharm"},{"key":"10.1016\/j.jtho.2016.06.029_bib22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","article-title":"Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer","volume":"31","author":"Welsh","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.06.029_bib27","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/cncr.20418","article-title":"The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma","volume":"101","author":"Lai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cllc.2012.06.004","article-title":"Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma","volume":"14","author":"Zhao","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemoth Pharm"},{"key":"10.1016\/j.jtho.2016.06.029_bib30","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1002\/cncr.28364","article-title":"Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations","volume":"119","author":"Hata","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib31","first-page":"1025","article-title":"Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases","volume":"35","author":"Hata","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2016.06.029_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","article-title":"High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer","volume":"99","author":"Clarke","year":"2010","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/JTO.0b013e318294c8e8","article-title":"Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer","volume":"8","author":"Lee","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.06.029_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1759-7714.12049","article-title":"Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports","volume":"5","author":"Xing","year":"2014","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.lungcan.2014.06.002","article-title":"Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis","volume":"85","author":"Lin","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2016.01.003","article-title":"Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer","volume":"93","author":"Tan","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib37","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.06.029_bib38","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.18632\/oncotarget.6758","article-title":"High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells","volume":"7","author":"Nanjo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2016.06.029_bib39","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate azd3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtho.2016.06.029_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lungcan.2012.09.016","article-title":"Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer","volume":"79","author":"Yang","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.029_bib41","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.18632\/oncotarget.3187","article-title":"Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy","volume":"6","author":"Zeng","year":"2015","journal-title":"Oncotarget"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416306268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416306268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T03:24:07Z","timestamp":1589685847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416306268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1556086416306268"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}